Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.76% |
| 2 | Technology | 16.41% |
| 3 | Consumer Staples | 10.58% |
| 4 | Consumer Discretionary | 10.12% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Gilead Sciences
GILD
$180B
| $685M | 0.59% |
8,901,247
-3,629,962
| -29% | -$278M |
2014 Q4
22 quarters
|
|
27
Molina Healthcare
MOH
$10.2B
| $654M | 0.56% |
3,676,459
-471,650
| -11% | -$80.3M |
2013 Q2
28 quarters
|
|
28
Incyte
INCY
$22.3B
| $652M | 0.56% |
6,271,350
+1,669,090
| +36% | +$161M |
2017 Q4
10 quarters
|
|
29
Hershey
HSY
$32.6B
| $651M | 0.56% |
5,025,538
-229,600
| -4% | -$30.9M |
2013 Q2
28 quarters
|
|
30
Vodafone
VOD
$37.9B
| $610M | 0.53% |
38,243,408
+2,100,500
| +6% | +$31.7M |
2015 Q3
19 quarters
|
|
31
Align Technology
ALGN
$9.82B
| $607M | 0.52% |
2,210,548
-727,681
| -25% | -$164M |
2013 Q2
28 quarters
|
|
|
HZNP
32
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $573M | 0.49% |
10,312,875
-310,800
| -3% | -$13.3M |
2017 Q2
12 quarters
|
|
33
Domino's
DPZ
$10.1B
| $569M | 0.49% |
1,539,725
-441,800
| -22% | -$163M |
2013 Q2
28 quarters
|
|
34
Regeneron Pharmaceuticals
REGN
$74.8B
| $555M | 0.48% |
890,100
+402,738
| +83% | +$229M |
2017 Q3
11 quarters
|
|
35
Exelixis
EXEL
$14.7B
| $546M | 0.47% |
23,006,910
+2,935,850
| +15% | +$68M |
2016 Q3
15 quarters
|
|
|
ABMD
36
DELISTED
Abiomed Inc
ABMD
| $544M | 0.47% |
2,250,122
+202,122
| +10% | +$40.6M |
2015 Q1
21 quarters
|
|
37
Cable One
CABO
$68.1M
| $543M | 0.47% |
305,900
-6,200
| -2% | -$11.1M |
2015 Q4
18 quarters
|
|
|
38
T-Mobile US
TMUS
$182B
| $539M | 0.47% |
5,175,106
+4,837,921
| +1,435% | +$464M |
2020 Q1
1 quarter
|
|
39
NetEase
NTES
$76.3B
| $533M | 0.46% |
6,210,680
+1,501,180
| +32% | +$113M |
2019 Q2
4 quarters
|
|
40
MarketAxess Holdings
MKTX
$5.78B
| $519M | 0.45% |
1,035,564
-165,800
| -14% | -$77.2M |
2016 Q4
14 quarters
|
|
|
ALXN
41
DELISTED
Alexion Pharmaceuticals
ALXN
| $503M | 0.43% |
4,479,243
+715,741
| +19% | +$76M |
2018 Q3
7 quarters
|
|
42
Herbalife
HLF
$1.34B
| $495M | 0.43% |
10,997,964
+1,315,061
| +14% | +$51.1M |
2015 Q3
19 quarters
|
|
43
Dropbox
DBX
$7.26B
| $484M | 0.42% |
22,225,426
+3,028,900
| +16% | +$64M |
2019 Q1
5 quarters
|
|
44
DexCom
DXCM
$31.7B
| $480M | 0.41% |
4,732,304
+934,988
| +25% | +$83.6M |
2018 Q1
9 quarters
|
|
45
Petrobras
PBR
$157B
| $474M | 0.41% |
57,313,130
-8,857,200
| -13% | -$64.2M |
2016 Q2
16 quarters
|
|
46
Etsy
ETSY
$6.8B
| $474M | 0.41% |
4,461,161
+212,100
| +5% | +$15.7M |
2015 Q4
18 quarters
|
|
47
United Therapeutics
UTHR
$22.5B
| $451M | 0.39% |
3,726,818
+136,595
| +4% | +$15.4M |
2013 Q2
28 quarters
|
|
48
Teradyne
TER
$63B
| $447M | 0.39% |
5,284,649
-556,701
| -10% | -$37.3M |
2015 Q4
18 quarters
|
|
49
F5
FFIV
$26.3B
| $438M | 0.38% |
3,136,774
+417,700
| +15% | +$56.2M |
2014 Q3
23 quarters
|
|
50
Icon
ICLR
$12.5B
| $433M | 0.37% |
2,568,719
+67,400
| +3% | +$10.6M |
2013 Q2
28 quarters
|
|
Similar funds
Renaissance Technologies's Q2 2020 Portfolio in Review
As of Q2 2020, Renaissance Technologies held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Renaissance Technologies withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,365 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 26% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Renaissance Technologies opened a new position in Uber worth $187M.
- Renaissance Technologies's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Renaissance Technologies added most to Zoom in Q2 2020, an estimated $806M increase.
- Renaissance Technologies's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Renaissance Technologies fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Renaissance Technologies's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Renaissance Technologies opened 584 new positions and closed 596 in Q2 2020.
- Renaissance Technologies's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.